Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Lymphoma, Non-Hodgkin

abstract

  • The full-dose combination of epratuzumab with rituximab was well tolerated and had significant clinical activity in NHL, suggesting that this combination should be tested in comparison with single-agent treatment.

publication date

  • December 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.13.821

PubMed ID

  • 15955901

Additional Document Info

start page

  • 5044

end page

  • 51

volume

  • 23

number

  • 22